drugset / Trial / NCT07490002
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, exploratory clinical study.
Timeline
- Start
- 2026-04-06
- Primary completion
- 2028-11-30
- Completion
- 2030-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Iparomlimab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | Tuvonralimab | Monoclonal antibody | 5 mg/kg | — |